Edition:
United States

Orexigen Therapeutics Inc (OREX.O)

OREX.O on Nasdaq

2.44USD
17 Aug 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$2.44
Open
$2.46
Day's High
$2.46
Day's Low
$2.36
Volume
34,215
Avg. Vol
104,838
52-wk High
$5.70
52-wk Low
$1.65

Latest Key Developments (Source: Significant Developments)

Valeant acquires Canadian rights for Contrave in treatment of obesity
Tuesday, 30 Aug 2016 08:00am EDT 

Valeant Pharmaceuticals International Inc : Valeant acquires the Canadian rights for Contrave® in the treatment of obesity . Valeant expects to file with health Canada for regulatory approval by January 2017 . Valeant will be responsible for obtaining Canadian regulatory approval and for all commercialization activities and expenses . Says Orexigen and Valeant anticipate launching Mysimba in 11 countries in Q4 of 2016 .Orexigen and Valeant anticipate launching Mysimba in 2 countries, in addition to 11 countries, in Q1 of 2017.  Full Article

Orexigen Therapeutics announces commercialization and distributorship agreement with Valeant Canada for Contrave
Tuesday, 30 Aug 2016 08:00am EDT 

Orexigen Therapeutics Inc :Orexigen Therapeutics announces commercialization and distributorship agreement with Valeant Canada for Contrave® (naltrexone hcl / bupropion hcl extended release).  Full Article

Orexigen Therapeutics announces Q2 loss per share $1.73
Thursday, 4 Aug 2016 04:01pm EDT 

Orexigen Therapeutics Inc : Orexigen Therapeutics reports business and financial results for the second quarter ended June 30, 2016 . Q2 revenue $7.8 million versus I/B/E/S view $6.9 million . Q2 loss per share $1.73 .Q2 earnings per share view $-1.47 -- Thomson Reuters I/B/E/S.  Full Article

Orexigen Therapeutics unit, ROVI announce agreement
Monday, 1 Aug 2016 08:30am EDT 

Orexigen Therapeutics Inc : "Expect mysimba to contribute to group's revenue in next few years" . Unit, Laboratorios Farmacéuticos Rovi S.A. executed commercialization and distributorship agreement for mysimba .Rovi expects to begin marketing mysimba by year-end 2016.  Full Article

Orexigen Therapeutics announces a 1-for-10 reverse stock split
Friday, 8 Jul 2016 04:02pm EDT 

Orexigen Therapeutics Inc : Orexigen therapeutics announces stockholder approval of all proposals at 2016 annual meeting and reverse stock split . Also announced a 1-for-10 reverse stock split .Expects that shares of orexigen will begin trading on a post-split basis on july 12, 2016.  Full Article

Orexigen Therapeutics Inc announces strategic acquisition of all U.S. rights to Contrave
Tuesday, 15 Mar 2016 07:00am EDT 

Orexigen Therapeutics Inc:Says entered into an agreement with Takeda Pharmaceutical Company Limited to acquire United States rights to Contrave.At the closing, Orexigen will pay Takeda $60 million to acquire Contrave U.S. rights.Following completion of transition period, Orexigen is required to pay Takeda an additional $15 million in first quarter 2017.Orexigen is also required to pay Takeda milestone payments upon achievement of certain levels of U.S. net sales of Contrave, the first of which, a $10 million payment, occurs when Contrave net sales reach $200 million in any calendar year.  Full Article

Orexigen Therapeutics Inc anounces commercialization and distributorship agreement with Valeant Pharmaceuticals for Mysimba
Tuesday, 15 Mar 2016 07:00am EDT 

Orexigen Therapeutics Inc:Anounces commercialization and distributorship agreement with Valeant Pharmaceuticals for Mysimba in Central and Eastern Europe.Orexigen expects Valeant to launch in the 12 EU countries in the second half of this year.  Full Article

BRIEF-Orexigen Therapeutics Q2 loss per share $2.00

* Orexigen Therapeutics announces second quarter 2017 financial results